Acta dermatovenerologica Croatica : ADC
-
Acta Dermatovenerol Croat · Dec 2018
Historical ArticleFrom the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
Everything included in this overview is a list of facts without analyses, which makes this a purely factual overview. The circumstances of the preparation for the foundation of the Croatian Dermatovenereological Society - the Croatian Medical Association (hereafter CDS-CMA) and the journal Acta Dermatovenerologica Croatica (hereafter ADC) Geopolitical changes in former Yugoslavia following 1990 and the Homeland War (1991-1995) led to new circumstances in almost all areas of social activity and the need for a restructuring and further development of professional physicians associations in our Homeland. In such new conditions, it was necessary to appropriately organize the professional work of our dermatovenerologists with the aim of founding and maintaining their professional ties to each other and to our colleagues abroad. ⋯ It is unnecessary to emphasize the importance of the fact that we have such a respectable journal in our Homeland. NOTE: The honorable duty of preparing this text was entrusted to me by the president of the CDVS-CMA, Prof. Mirna Šitum, PhD, at the meeting of the Executive Board of CDVS-CMA held on the 16th of April 2012 (for the purposes of an oral presentation of this data at the 3rd Croatian Congress of Psychodermatology with international participation, Split, 4-7 October, 2012, and again at the meeting of the Executive Board of CDVS-CMA, held on the 7th of June 2013 for the purposes of the web page of CDVS-CMA).
-
Acta Dermatovenerol Croat · Dec 2018
Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Dear Editor, Immune-checkpoint blockade is a type of passive immunotherapy aimed at enhancing preexisting anti-tumor responses of the organism, blocking self-tolerance molecular interactions between T-lymphocytes and neoplastic cells (1,2). Despite a significant increase in progression-free survival, a large proportion of patients affected by metastatic melanoma do not show durable responses even after appropriate diagnostic categorization and shared therapeutic choices (3-9). Therefore, predictive biomarkers of clinical response are urgently needed, and predictive immunohistochemistry (IHC) meets these requirements. ⋯ S. Food and Drug Administration has approved the use of pembrolizumab in 2017 for unresectable or metastatic solid tumors with MMR deficiency (14). In conclusion, dMMR melanoma seems to be a particular subset of disease that can be identified with high sensibility and specificity by predictive IHC as a complete loss of one or more DNA MMR proteins and that deserves targeted therapy.